Vera Therapeutics, Inc. (VERA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$35.89+2.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VERA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 261.9 | 215.3 | 126.2 | 78.2 | 69.0 | 22.5 | 45.2 |
| Operating Income | (415.8) | (315.5) | (167.2) | (102.0) | (90.9) | (34.4) | (52.2) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 7.5 | 7.6 | 3.8 | 1.0 | 0.0 | 0.2 |
| Interest & Investment Income | 23.0 | 24.5 | 20.7 | 8.0 | 1.8 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | (4.2) | (0.8) | 0.0 | 0.2 |
| Other Non-Operating Income / Expenses | 13.9 | 15.9 | 15.0 | 6.0 | 1.8 | 1.8 | (1.2) |
| EBT, Incl. Unusual Items | — | (299.6) | (152.1) | (96.0) | (89.1) | (32.6) | (53.4) |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.0) |
| Net Income | |||||||
| Net Income | (401.9) | (299.6) | (152.1) | (96.0) | (89.1) | (32.6) | (53.4) |
| Per Share | |||||||
| Basic EPS | (5.59) | (4.66) | (2.75) | (2.25) | (3.35) | (2.43) | — |
| Diluted EPS | (5.59) | (4.66) | (2.75) | (2.25) | (3.35) | (2.43) | — |
| Basic Weighted Avg Shares | 71.8 | 64.2 | 55.3 | 42.7 | 26.6 | 13.4 | — |
| Diluted Weighted Avg Shares | 71.8 | 64.2 | 55.3 | 42.7 | 26.6 | 13.4 | — |
| Supplemental | |||||||
| EBITDA | — | (315.0) | (167.1) | (102.0) | (91.7) | (34.2) | (52.0) |
| EBIT | (415.8) | (315.5) | (167.2) | (102.0) | (90.9) | (34.4) | (52.2) |
| Effective Tax Rate | — | — | — | -0.0% | -0.0% | -0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.